Efficacy of FOLFIRI plus bevacizumab versus FOLFIRI plus cetuximab in RAS-mutant metastatic colorectal cancer: Final update on patients with RAS-mutant metastatic colorectal cancer treated in FIRE-3

被引：0
|
作者：
Weiss, Lena
Stintzing, Sebastian
Modest, Dominik Paul
von Weikersthal, Ludwig
Decker, Thomas
Kiani, Alexander
Vehling-Kaiser, Ursula
Al-Batran, Salah-Eddin
Heintges, Tobias
Lerchenmuller, Christian A.
Kahl, Christoph
Seipelt, Gernot
Kullmann, Frank
Moehler, Markus H.
Scheithauer, Werner
Held, Swantje
Miller-Phillips, Lisa
Stahler, Arndt
Jung, Andreas
Heinemann, Volker
机构：
[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany
[2] Charit Univ Med Berlin, Hematol Oncol & Canc Immunol CCM, Berlin, Germany
[3] Charite Univ Med Berlin, Dept Hematol Oncol & Canc Immunol, Berlin, Germany
[4] Gesundheitszentrum St Marien GmbH, Amberg, Germany
[5] Onkol Ravensburg, Ravensburg, Germany
[6] Klinikum Bayreuth GmbH, Dept Hematol & Oncol, Bayreuth, Germany
[7] Comprehens Canc Ctr EMN, Erlangen, Germany
[8] Practice Med Oncol, Landshut, Germany
[9] Univ Canc Ctr Germany, Frankfurt Inst Clin Canc Res, Krankenhaus Nordwest, Frankfurt, Germany
[10] Stadtische Kliniken Neuss, Neuss, Germany
[11] Hamatolog Onkolog, Greven, Germany
[12] Klinikum Magdeburg, Dept Hematol, Magdeburg, Germany
[13] Onkolog Schwerpunktpraxis, Dreieich, Germany
[14] Klinikum Weiden, Dept Med 1, Weiden, Germany
[15] Johannes Gutenberg Univ Clin, Mainz, Germany
[16] Med Univ Vienna, Vienna, Austria
[17] Clinassess Inc, Leverkusen, Germany
[18] Univ Munich, LMU Klinikum, Munich, Germany
[19] Charit Univ Med Berlin, Berlin, Germany
[20] Free Univ Berlin, Berlin, Germany
[21] Humboldt Univ, Berlin, Germany
[22] Dept Hematol Oncol & Canc Immunol, Berlin, Germany
[23] Univ Munich, Inst Pathol, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3550
引用
收藏
页数：1
相关论文
共 50 条
  • [41] FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial
    Heinemann, Volker
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Kaiser, Florian
    Al-Batran, Salah-Edin
    Heintges, Tobias
    Lerchenmuller, Christoph
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Moehler, Markus
    Scheithauer, Werner
    Held, Swantje
    Miller-Phillips, Lisa
    Modest, Dominik Paul
    Jung, Andreas
    Kirchner, Thomas
    Stintzing, Sebastian
    BRITISH JOURNAL OF CANCER, 2021, 124 (03) : 587 - 594
  • [42] Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients
    Mitsukuni Suenaga
    Satoshi Matsusaka
    Masashi Ueno
    Noriko Yamamoto
    Eiji Shinozaki
    Nobuyuki Mizunuma
    Toshiharu Yamaguchi
    Kiyohiko Hatake
    Surgery Today, 2011, 41 : 1067 - 1074
  • [43] Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer
    Yoshihiro, Tomoyasu
    Kusaba, Hitoshi
    Makiyama, Akitaka
    Kobayashi, Kazuma
    Uenomachi, Masato
    Ito, Mamoru
    Doi, Yasuhiro
    Mitsugi, Kenji
    Aikawa, Tomomi
    Takayoshi, Kotoe
    Esaki, Taito
    Shimokawa, Hozumi
    Tsuchihashi, Kenji
    Ariyama, Hiroshi
    Akashi, Koichi
    Baba, Eishi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (05) : 508 - 515
  • [44] Safety, efficacy, and time to clinical response with bevacizumab plus FOLFIRI regimen in metastatic colorectal cancer
    Tomao, S., Sr.
    Spinelli, G.
    Rossi, L.
    Pasciuti, G.
    Arcangeli, G.
    D'Aprile, M.
    Veltri, E.
    Baiano, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
    A. Fernández Montes
    E. Élez
    A. Vivancos
    N. Martínez
    P. González
    M. Covela
    J. de la Cámara
    A. Cousillas
    J. C. Méndez
    B. Graña
    E. Aranda
    Clinical and Translational Oncology, 2022, 24 : 1209 - 1214
  • [46] Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
    Fernandez Montes, A.
    Elez, E.
    Vivancos, A.
    Martinez, N.
    Gonzalez, P.
    Covela, M.
    de la Camara, J.
    Cousillas, A.
    Mendez, J. C.
    Grana, B.
    Aranda, E.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (06): : 1209 - 1214
  • [47] About RAS Mutation Clearance in Plasma ctDNA From RAS-Mutant Colorectal Cancer Patients Reply
    Bouchahda, Mohamed
    Saffroy, Raphael
    Karaboue, Abdoulaye
    Hamelin, Jocelyne
    Innominato, Pasquale
    Saliba, Faouzi
    Bosselut, Nelly
    Lemoine, Antoinette
    Levi, Francis
    JCO PRECISION ONCOLOGY, 2021, 5 : 391 - 392
  • [48] Retrospective analysis of patients treated with cetuximab plus FOLFIRI for previous irinotecan combined chemotherapy in metastatic colorectal cancer
    Woo, Jae P.
    Eun-joo, J.
    Sun-mi, M.
    Dae-yong, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 95 - 95
  • [49] ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress
    Wainberg, Z.
    Wang, L.
    Yue, H.
    Motwani, M.
    Kasichayanula, S.
    Blaney, M.
    Naumovski, L.
    Strickler, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
12345